Natural killer cell engagers for cancer immunotherapy

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Natural killer (NK) cells are crucial for innate immunity and cancer surveillance.
• Conventional monoclonal antibodies (mAbs) primarily enhance Antibody-Dependent Cellular Cytotoxicity (ADCC) via Fc-CD16a interactions.
• Existing immunotherapies face challenges in overcoming tumor immune evasion and enhancing NK cell function.

Purpose of the Study:

• To review the engineering strategies and therapeutic potential of bi-, tri-, and multi-specific NK cell engagers (NKCEs) in cancer immunotherapy.
• To analyze advancements in NKCE platform technologies and their preclinical and clinical progress.
• To discuss the future prospects and challenges of NKCEs in revolutionizing cancer treatment.

Main Methods:

• Literature review of scientific publications and industry reports on NKCEs.
• Analysis of NKCE engineering strategies targeting NK cell receptors and tumor-associated antigens.
• Evaluation of preclinical and clinical data on NKCE efficacy and safety.

Main Results:

• NKCEs establish robust, multi-receptor engagement with NK cells, surpassing traditional mAb mechanisms.
• Engineered NKCEs demonstrate enhanced specificity and efficacy in killing cancer cells.
• Various NKCE platform technologies are under active development by pharmaceutical and biotech companies.

Conclusions:

• NKCEs represent a promising advancement in cancer immunotherapy, enhancing NK cell-mediated cytotoxicity.
• Further research is needed to optimize NKCE therapeutic efficacy and address NK cell dysfunction in cancer patients.
• NKCEs hold significant potential to transform cancer treatment paradigms.